Estimated 67 patient convalescent plasma late treatment RCT with results not reported over 4 years after estimated completion.
1.
Baylor Research Institute, Evaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19, NCT04333251, clinicaltrials.gov/study/NCT04333251.
2.
Perner et al., Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure - the COVID PLEX+CCP Trial, NCT04634422, clinicaltrials.gov/study/NCT04634422.
3.
Itinose et al., Validation Protocol for The Clinical Use of Convalescent Plasma for Hospitalized Patients With COVID-19. A Prospective Study at a Hospital in Southern Brazil., NCT05077930, clinicaltrials.gov/study/NCT05077930.
4.
Rego et al., Efficacy and Safety of Using Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support, NCT04528368, clinicaltrials.gov/study/NCT04528368.
5.
Dillner et al., Convalescent Plasma for Treatment of COVID-19: An Open Randomised Controlled Trial, NCT04649879, clinicaltrials.gov/study/NCT04649879.
6.
ElDesouky et al., Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection, NCT04438694, clinicaltrials.gov/study/NCT04438694.
7.
Karyana et al., Clinical Trial of Convalescent Plasma Administration as Adjunct Therapy for COVID-19 (Uji Klinik Pemberian Plasma Konvalesen Sebagai Terapi Tambahan COVID-19), NCT04873414, clinicaltrials.gov/study/NCT04873414.
8.
de la Puerta Rueda et al., Clinical Efficacy of the Infusion of Donor Plasma, Convalescent From SARS-CoV-2 Infection, to Patients With Recent Infection., NCT05247307, clinicaltrials.gov/study/NCT05247307.
9.
Perilla et al., Efficacy of Convalescent Plasma for the Treatment of Severe SARS-CoV-2 Infection: A Randomized, Open Label Clinical Trial, NCT04391101, clinicaltrials.gov/study/NCT04391101.
10.
Keitel-Anselmino et al., Reconvalescent Plasma / Camostat Mesylate Early in Sars-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals, NCT04681430, clinicaltrials.gov/study/NCT04681430.
11.
Schiffer et al., Randomized Controlled Phase 2b Clinical Study in Parallel Groups for the Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma Plus Standard Treatment vs. Standard Treatment Alone of Subjects With Severe COVID-19, NCT04712344, clinicaltrials.gov/study/NCT04712344.
12.
Pathak et al., A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications, NCT04374487, clinicaltrials.gov/study/NCT04374487.
13.
Kaufman et al., A Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients With COVID-19 of Moderate Severity, NCT04361253, clinicaltrials.gov/study/NCT04361253.
14.
Gonzalez et al., Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma, NCT04468009, clinicaltrials.gov/study/NCT04468009.
15.
Martinaud et al., Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units., NCT04372979, clinicaltrials.gov/study/NCT04372979.
16.
Talarico et al., Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection, NCT04385043, clinicaltrials.gov/study/NCT04385043.
17.
Herrick et al., Infusion of Convalescent Plasma for the Treatment of Patients Infected With Severe Acute Respiratory Syndrome-Coronavirus-2 (COVID-19): A Double-blinded, Placebo-controlled, Proof-of-concept Study, NCT04442191, clinicaltrials.gov/study/NCT04442191.
18.
Camacho-Ortiz et al., Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia, NCT04358783, clinicaltrials.gov/study/NCT04358783.
19.
Fundacin Biomedica Galicia Sur, PHASE II Clinical Trial Randomized And Controlled To Assess Need Of Oxygen On Day 14 After Administration Of Passive Immunotherapy In Patients Infected By SARS-CoV-2 With Risks Factors For Severe Disease, NCT05578391, clinicaltrials.gov/study/NCT05578391.
20.
Torres et al., A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU), NCT04547127, clinicaltrials.gov/study/NCT04547127.
21.
Quintero-Vega et al., Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19: A Randomized, Controlled Study CRI-CP (Coronavirus Investigation - Convalescent Plasma), NCT04425837, clinicaltrials.gov/study/NCT04425837.
22.
Sierra-Madero et al., Phase 2b/3 Trial to Evaluate the Safety and Efficacy of Plasma Transfusion From Convalescent Patients With SARS-CoV-2 Infection on Severity and Mortality of COVID-19 in Hospitalized Patients, NCT04388410, clinicaltrials.gov/study/NCT04388410.
23.
Zuluaga et al., Inactivated Convalescent Plasma as a Therapeutic Alternative in Hospitalized Patients CoViD-19, NCT04385186, clinicaltrials.gov/study/NCT04385186.
24.
Cardesa Gil et al., Phase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection, NCT04366245, clinicaltrials.gov/study/NCT04366245.
25.
Lubis et al., Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia, NCT04380935, clinicaltrials.gov/study/NCT04380935.
26.
Chowdhury et al., Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT, NCT04403477, clinicaltrials.gov/study/NCT04403477.
27.
Torres (B) et al., Convalescent Plasma as a Treatment for Patients With Severe COVID-19 Disease, NCT04542967, clinicaltrials.gov/study/NCT04542967.
ElDesouky et al., 31 Dec 2021, Randomized Controlled Trial, Egypt, trial NCT04438694 (history) (CP IN COVID19).
Contact: nermeen.eldesoukey@kasralainy.edu.eg.
Late treatment
is less effective
is less effective
